CLINICAL CASE OF REPLACEMENT OF ENDOTHELIN RECEPTOR ANTAGONIST (BOSENTAN) BY SOLUBLE GUANYLATE CYCLASE STIMULATOR (RIOCIGUAT) IN THE PATIENT WITH PULMONARY ARTERIAL HYPERTENSION

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by progressive increase in pulmonary vascular resistance (PVR), higher pulmonary arteries mean pressure (mPAP), decrease in cardiac minute output (CMO) and other hemodynamic, functional and biochemical disorders. Exist...

Descripció completa

Dades bibliogràfiques

Autors principals:	E. A. Devetyarova, A. A. Dyuzhikov, A. A. Dyuzhikova, S. V. Sobin, A. V. Sumin, E. V. Pashchenko
Format:	Artigo
Idioma:	Russo
Publicat:	InterMedservice 2018-06-01
Col·lecció:	Евразийский Кардиологический Журнал
Matèries:	pulmonary hypertension pulmonary arterial hypertension riociguat bosentan therapy
Accés en línia:	https://www.heartj.asia/jour/article/view/287
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!